Bionano announces software marketing agreement with revvity for newborn sequencing research

Bionano has entered into a software marketing agreement with revvity, inc. (revvity) under which revvity will market and commercialize bionano's via™ software to revvity's next generation sequencing (ngs) customers as part of its newborn sequencing research workflow via is expected to enhance revvity's newborn sequencing solution by adding an assessment of copy number variation (cnv) to the ngs solution report and streamlining the workflow's interpretation capabilities san diego, june 20, 2024 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo), today announced that it has entered into a software marketing agreement with revvity, inc. (nyse: rvty) under which revvity will market and commercialize bionano's via™ software as part their newborn sequencing research workflow. via is expected to enhance the comprehensive reporting capabilities of revvity's sequencing solution by adding an assessment of cnvs to its ngs workflow and streamlining the workflow's interpretation capabilities.
BNGO Ratings Summary
BNGO Quant Ranking